Abstract
Siglecs (sialic acid-binding immunoglobulin-like lectins) are a family of vertebrate glycan-binding cell-surface proteins. The majority mediate cellular inhibitory activity once engaged by specific ligands or ligand-mimicking molecules. As a result, Siglec engagement is now of interest as a strategy to therapeutically dampen unwanted cellular responses. When considering allergic inflammation, human eosinophils and mast cells express overlapping but distinct patterns of Siglecs. For example, Siglec-6 is selectively and prominently expressed on mast cells while Siglec-8 is highly specific for both eosinophils and mast cells. This review will focus on a subset of Siglecs and their various endogenous or synthetic sialoside ligands that regulate eosinophil and mast cell function and survival. It will also summarize how certain Siglecs have become the focus of novel therapies for allergic and other eosinophil- and mast cell-related diseases.
| Original language | English (US) |
|---|---|
| Article number | 101799 |
| Journal | Seminars in Immunology |
| Volume | 69 |
| DOIs | |
| State | Published - Sep 2023 |
Funding
This research was funded, at least in part, by The Mastocytosis Society and the American Academy of Allergy, Asthma and Immunology (to J.A.O.); the Ernest S. Bazley Charitable Fund (to R.P.S.); the National Heart, Lung, and Blood Institute ( P01 HL107151 to B.S.B.); and the National Institute of Allergy and Infectious Diseases ( R01 AI137174 and P01 AI145818 to R.P.S.; U19 AI136443 and R21 AI159586 to B.S.B., and U19 AI070535 subaward 107905120 to J.A.O.).
Keywords
- Allergy
- CD22
- CD33
- Eosinophils
- IgE
- Mast cells
- Siglec-6
- Siglec-8
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
